TRIMETHOBENZAMIDE HYDROCHLORIDE Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Trimethobenzamide Hydrochloride, and what generic alternatives are available?
Trimethobenzamide Hydrochloride is a drug marketed by Avet Lifesciences, Lupin, Sun Pharm Industries, Am Regent, Hospira, Smith And Nephew, Solopak, and Watson Labs. and is included in eleven NDAs.
The generic ingredient in TRIMETHOBENZAMIDE HYDROCHLORIDE is trimethobenzamide hydrochloride. There are six drug master file entries for this compound. Ten suppliers are listed for this compound. Additional details are available on the trimethobenzamide hydrochloride profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Trimethobenzamide Hydrochloride
A generic version of TRIMETHOBENZAMIDE HYDROCHLORIDE was approved as trimethobenzamide hydrochloride by LUPIN on August 20th, 2003.
Summary for TRIMETHOBENZAMIDE HYDROCHLORIDE
US Patents: | 0 |
Applicants: | 8 |
NDAs: | 11 |
Finished Product Suppliers / Packagers: | 6 |
Raw Ingredient (Bulk) Api Vendors: | 68 |
Clinical Trials: | 4 |
Patent Applications: | 422 |
Formulation / Manufacturing: | see details |
DailyMed Link: | TRIMETHOBENZAMIDE HYDROCHLORIDE at DailyMed |
Recent Clinical Trials for TRIMETHOBENZAMIDE HYDROCHLORIDE
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
Kyowa Kirin | Phase 2 |
Indiana University | Phase 2 |
Pfizer | Phase 1 |
Pharmacology for TRIMETHOBENZAMIDE HYDROCHLORIDE
Drug Class | Antiemetic |
Physiological Effect | Emesis Suppression |